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TumorigenicityKrüppel-like factor 4 (KLF4) functions as either a tumor suppressor or an oncogene in different tis-
sues by regulating the expression of various genes. The aim of this study was to reveal the functions
of KLF4 in regulating breast cancer apoptosis, proliferation, and tumorigenic progression. KLF4
expression levels in breast cancer tissues and breast cancer cell lines were found to be much lower
than those in nontumorous tissues and a nontransformed mammary epithelial cell line. KLF4 was
upregulated in the tumor necrosis factor-a–induced SK-BR-3 breast cancer cell apoptotic process.
Overexpression of KLF4 promoted SK-BR-3 breast cancer cell apoptosis and suppressed SK-BR-3 cell
tumorigenicity in vivo.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer remains a major health problem with respect to
malignancy and is composed of distinct biological subtypes with
diverse clinical, pathological, molecular, and genetic features as
well as different therapeutic responsiveness and outcomes [1,2].
Despite this clinical importance, the exact pathological processes
of tumor proliferation and metastasis remain poorly understood,
and deciphering the exact molecular mechanisms of these
processes is of paramount importance to identifying speciﬁc
therapeutic targets for this devastating disease.
Krüppel-like factor 4 (KLF4), a zinc ﬁnger-containing transcrip-
tion factor, is expressed in a variety of tissues [3,4]. KLF4
regulates numerous biological processes, including proliferation,differentiation, apoptosis, migration, invasion, and the blood-
tumor barrier [4–7]. In addition, KLF4 plays an important role in
reprogramming differentiated somatic cells into induced pluripo-
tent stem cells (iPSCs) [8–10]. The role of KLF4 in cancers remains
controversial [11–14]. In renal cell cancer, KLF4 is a putative tumor
suppressor gene and is epigenetically silenced by promoter CpG
methylation [5]. In hepatocellular carcinoma, KLF4 suppresses
SLUG transcription and acts as a tumor suppressor. KLF4 is down-
regulated in colon cancer tissues and may serve as a prognostic
biomarker [15]. KLF4 also acts as a tumor suppressor in prostate
cancer, cervical carcinoma, and pancreatic ductal carcinoma [16–
18]. Several studies have revealed that KLF4 participates in the
maintenance of breast cancer stem cells as well as metastasis
and invasion in breast cancer [19–21]. However, KLF4 was also
shown to inhibit tumorigenic progression and metastasis in a
mouse model of HER2/NEU/ERBB2-positive breast cancer [22]
and to suppress estrogen-dependent breast cancer growth by
inhibiting the transcriptional activity of estrogen receptor alpha
[23]. Moreover, KLF4 is transcriptionally activated by p53 follow-
ing DNA damage and is considered to participate in apoptosis in
breast cancer cells [23]. KLF4 is signiﬁcantly downregulated during
epithelial–mesenchymal transition (EMT) in mammary epithelial
cells and breast cancer cells and plays a central role in the mainte-
nance of epithelial cell differentiation and the prevention of EMT
and metastasis [24,25].
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breast cancer tissues and several breast cell lines, detected the
potential role of KLF4 in SK-BR-3 breast cancer cell apoptosis,
and investigated the role of KLF4 in tumorigenic progression by
transient adenoviral expression of KLF4 in a xenograft model.
2. Materials and methods
2.1. Cell culture, breast cancer cell lines, and clinical samples
The mammary epithelial cell line HBL-100 and breast cancer
cell lines MCF-7, SK-BR-3, and MDA-MB-231 were obtained from
Cell Resource Center of Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences, China. HBL-100 cells were
cultured in RPMI-1640 supplemented with 10% fetal bovine serum
(FBS; HyClone, Logan, UT, USA). MCF-7 and SK-BR-3 cells were
maintained in Dulbecco’s Modiﬁed Eagle’s Medium with 10% FBS,
and MDA-MB-231 cells were maintained in L-15 Medium with
10% FBS. All cell lines were cultured in a humidiﬁed atmosphere
with 5% CO2 at 37 C.
Human breast cancer samples and their nontumorous counter-
parts were collected from patients with breast cancer who under-
went surgical resection at Hebei University Afﬁliated Hospital
between June 2013 and December 2013. Tumor stage was classi-
ﬁed according to National Comprehensive Cancer Network guide-
lines, and all cases were found to be inﬁltrating ductal carcinoma
stage II. The resected tissues were immediately snap-frozen in liq-
uid nitrogen and stored at 80 C or ﬁxed in 10% neutral-buffered
formalin and embedded in parafﬁn. Written informed consent was
obtained from patients, and approval of the use of human speci-
mens in this study was obtained from the Institutional Review
Board of Hebei University Afﬁliated Hospital.
2.2. Immunohistochemical staining
A manual immunohistochemical procedure was applied using
tissue sections with a thickness of 4 lm. After deparafﬁnization
in xylene and rehydration in graded ethanol, endogenous
peroxidase was blocked with 3% aqueous H2O2 for 25 min. Then
heat-induced antigen retrieval was accomplished by immersing
the slides in 10 mM citrate buffer, pH 6, at 120 C for 10 min. The
slides were incubated with the anti-KLF4 antibody (sc-20691,
dilution: 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4 C. Then the slides were washed four times,
processed with ready-to-use peroxidase-conjugated antibodies for
30 min at room temperature, developed with 3,30-diaminobenzidine
as a chromogen, and counterstained with hematoxylin. The results
were reviewed independently by two pathologists. As negative
controls, slides were treated by replacing the primary antibody
with nonimmune serum.
The expression of KLF4 was determined using a semiquantita-
tive visual approach. Immunostaining scoring was performed
while blinded to patients’ information and outcomes. The percent-
age of positive tumor cells was determined semiquantitatively by
assessing the entire slide. Each sample was assigned to
one of the following categories: 0 (0–4%), 1 (5–24%), 2 (25–49%),
3 (50–74%), or 4 (75–100%). The intensity of immunostaining
was determined as 0 (negative), 1 (weak), 2 (moderate), or 3
(strong). Immunostaining score formula = score of positive cell
percentage  score of staining intensity.
2.3. Adenovirus expression vector and plasmid construction
The human KLF4 cDNA (accession NM_004235.4) was cloned
into the pEGFP-C2 plasmid to create the pEGFP-KLF4 expressionvector, and the KLF4 cDNA sequence was conﬁrmed by sequencing.
For the adenovirus expression vector, the GFP-KLF4 or green ﬂuores-
cent protein (GFP) cDNA was cloned into the pAD/CMV/V5-DEST
vector (Invitrogen, Carlsbad, CA, USA) to create the GFP-KLF4
and GFP adenovirus pAd-GFP-KLF4 and pAd-GFP. The resulting
constructs were packaged in A293 cells by transfection with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions to generate an adenoviral stock. Then the adenovirus
was ampliﬁed by infecting with A293 cells, and culture
supernatant from A293 cells with a titer of 3  108 pfu/mL was
used to infect breast cancer cells. After adenovirus delivery, GFP
and GFP-KLF4 were detected using Western blot analysis.
2.4. siRNA transfection
Nonspeciﬁc siRNA (si-NS) and the siRNAs speciﬁc for human
KLF4 were purchased from Santa Cruz Biotechnology.
Transfection was performed using Lipofectamine (Invitrogen) fol-
lowing the manufacturer’s instructions. After the indicated times
of transfection, HBL-100 cells were harvested and subjected to
Western blotting and MTS proliferation analysis.
2.5. RNA preparation and quantitative RT-PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s instructions. Complementary DNA was
synthesized from the total RNA (0.5 lg) using the Moloney
Murine Leukemia Virus Reverse Transcriptase (Promega,
Madison, WI, USA) following the manufacturer’s instructions.
Subsequently, quantitative reverse transcription polymerase chain
reaction (RT-PCR) of KLF4 was performed using the Platinum SYBR
Green quantitative PCR SuperMix UDG Kit (Invitrogen). Each RT-
PCR consisted of 2 lL diluted RT product, 10 lL SYBR Green PCR
Master Mix, and 250 nM forward and reverse primers in a total vol-
ume of 20 lL. Reactions were carried out on a 7300 RT-PCR System
(Applied Biosystems, Foster City, CA, USA) for 40 cycles (95 C for
5 s, 60 C for 40 s) after an initial 2-min incubation at 95 C. As
an internal control, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) gene primers were used for RNA template normalization.
The relative expression level was calculated using the following
equation: relative gene expression = 2 – (DCtSample – DCtControl)
[4]. The following primers were used: KLF4, 50-ATCTTTCTCCAC
GTTCGCGTCTG-30 (sense) and 50-AAGCACTGGGGGAAGTCGCTT
C-30 (antisense); GAPDH, 50-AAGGTCGGAGTCAACGGATTT-30
(sense) and 50-ACCAGAGTTAAAAGCAGCCCTG-30 (antisense).
Experiments were performed at least three times with samples
analyzed in triplicate.
2.6. Western blotting
Western blotting was carried out as described previously [26].
Brieﬂy, crude proteins were extracted, resolved by sodium dodecyl
sulfate polyacrylamide gel electrophoresis, and transferred onto a
polyvinylidene diﬂuoride membrane (Millipore, Billerica, MA,
USA). Membranes were blocked with 5% milk in Tris-buffered sal-
ine with Tween 20 for 2 h at 37 C and then incubated overnight at
4 C with the following primary antibodies: rabbit anti-KLF4
(1:400, Santa Cruz Biotechnology), rabbit anti-cleaved caspase-3
(1:500, Proteintech, Chicago, IL, USA), rabbit anti-bax (1:500,
Proteintech), or mouse anti-b-actin (1:1000, Santa Cruz
Biotechnology). After incubation with the appropriate secondary
antibody, the immunoreactive signal of antibody–antigen pairs
was visualized using the Chemiluminescence Plus Western Blot
analysis kit (Santa Cruz Biotechnology). Experiments were
performed at least three times.
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The MTS cell proliferation assay was performed using the com-
mercially available CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega). About 1  104 cells were seeded in
96-well plates and grown for the indicated times. Then, 20 ll
MTS reagent was added to each well, and the plate was incubated
in the dark for 2 h before detection. The absorbance was measured
in a Thermo Fluroscan Ascent spectrometer at 490 nm.
Experiments were performed at least three times.
2.8. Assessment of apoptosis by ﬂow cytometry
Cells were stained with phycoerythrin (PE) annexin V and 7-
amino-actinomycin (PE Annexin V Apoptosis Detection Kit I; BD
Biosciences, Franklin Lakes, NJ, USA) as recommended by the
manufacturer. A total of 10,000 ﬂuorescent events were acquired
using a ﬂuorescence-activated cell sorting (FACS)-Calibur equipped
with CellQuest Pro software (BD Biosciences).
2.9. Animal model of breast cancer xenograft
Nude mice were subcutaneously injected as described
previously [27]. Female BALB/c-nu mice, 4–6 weeks old, were pur-
chased from the Beijing HFK Bioscience Co., Ltd (Beijing, China). All
of the mice were bred and housed in a speciﬁc pathogen-free
environment at Hebei University Laboratory Animal Research
Center. All experiments were approved by the Animal Research
Ethics Committee of the authors’ institution. SK-BR-3 breast cancer
cells were added with pAd-GFP, pAd-GFP-KLF4, or PBS for 24 h,
and GFP- or GFP-KLF4-overexpressing SK-BR-3 cells andFig. 1. KLF4 expression was signiﬁcantly decreased in breast cancer tissues and breast
cancer, total RNA was isolated, and quantitative RT-PCR was performed to evaluate KLF
cancer tissues and adjacent tissues were detected by immunohistochemical staining. M
staining scores. ⁄P < 0.05 vs control group. (C) KLF4 mRNA levels in breast cancer cell line
RT-PCR. Experiments were performed at least three times. ⁄P < 0.05 vs HBL-100 group. (
with anti-KLF4 antibody. b-Actin was used as a control for equal protein loading. Left, Blot
b-actin. Bars represent the mean ± SEM from 3 independent experiments. ⁄P < 0.05 vs Hnull-overexpressing SK-BR-3 cells were obtained. The cells were
suspended in their regular medium separately. Then, 100 lL of sus-
pensions containing 5  106 cells was injected subcutaneously into
the right mammary fat pad of a nude mouse. Each experimental
group was tested in a group of 5 mice. The size of the tumor formed
was monitored closely and measured every 2 days using a caliper.
The volume of the tumors was estimated according the formula:
Volume = 1/2  a  b2, where a and b represent the largest and
smallest diameters, respectively [28]. The mice were sacriﬁced
14 days after injection. Tumors were harvested, measured,
weighed, and photographed.
2.10. Statistical analyses
Data are presented as histograms of means ± standard error of
the mean (SEM) values for data from three or more independent
experiments. Statistical analyses were performed using the
Student’s t-test or one-way analysis of variance (ANOVA) according
to the number of groups compared. Student–Newman–Keuls (SNK)
test was used to test speciﬁc differences after the ANOVA for post
hoc analysis. Differences were considered signiﬁcant at P < 0.05.3. Results
3.1. KLF4 expression was signiﬁcantly decreased in breast cancer
tissues and breast cells
To explore whether KLF4 is associated with breast cancer, KLF4
messenger RNA (mRNA) expression levels were detected in breast
inﬁltrating ductal carcinoma tissues and adjacent normal breastcells. (A) Samples and adjacent tissues were obtained from 16 patients with breast
4 mRNA levels. ⁄P < 0.05 vs adjacent tissue group. (B) KLF4 protein levels in breast
agniﬁcation 200. Left, representative photographs; right, immunohistochemical
s and a nontransformed mammary epithelial cell line were detected by quantitative
D) Crude proteins were extracted from the cells and subjected to Western blotting
s from a representative experiment. Right, Densitometry; results were normalized to
BL-100 group.
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from 16 patients were collected, total RNA was isolated, and
quantitative RT-PCR was performed to evaluate KLF4 expression
levels. As shown in Fig. 1A, KLF4 mRNA expression levels in breast
cancer tissues were much lower than those in their nontumorous
counterpart tissues. KLF4 protein levels were detected by immuno-
histochemical analysis. The results revealed that KLF4 was
expressed in normal breast tissues. However, the expression of
KLF4 can hardly be detected in breast cancer tissues (Fig. 1B).
Furthermore, KLF4 expression was low in breast cancer cell lines
(SK-BR-3, MCF-7, and MDA-MB-231) compared with theFig. 2. KLF4 was upregulated in TNF-a–stimulated SK-BR-3 breast cancer cells. (A) SK-BR
for 24 h. Total RNA was isolated and subjected to qRT-PCR. Bars represent the mean ± SE
and MDA-MB-231 breast cancer cells were treated with 10 ng/mL TNF-a for 24 h. Crude p
anti-KLF4 antibody. b-Actin was used as a control for equal protein loading. Left, Blots fro
actin. Bars represent the mean ± SEM from 3 independent experiments. ⁄P < 0.05 vs cont
indicated times (0, 6, 12, 24, and 34 h). Crude proteins were extracted from the treated cel
as a control for equal protein loading. Upper, Blots from a representative experiment. Low
from 3 independent experiments. ⁄P < 0.05 vs control group. (D) SK-BR-3 cells were trea
using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit. The absorb
transfected with si-KLF4 or si-NS for 24 h and then treated with 10 ng/mL TNF-a for 48 h
Kit. One representative experiment is shown (upper); the results from 3 independent ex
cancer cells were treated with 10 ng/mL TNF-a for 0, 6, 12, and 24 h. Crude proteins were
against cleaved caspase-3 and Bax. b-Actin was used as a control for equal protein load
control group.expression in a nontransformed mammary epithelial cell line
(HBL-100) (Fig. 1C and D).
3.2. KLF4 was upregulated in TNF-a–stimulated SK-BR-3 breast cancer
cells
To explore the actual roles of KLF4 in breast cell proliferation
and apoptosis, we ﬁrst examined the expression of KLF4 in TNF-
a–stimulated SK-BR-3, MCF-7, and MDA-MB-231 breast cancer cell
lines. KLF4 mRNA and protein levels were increased signiﬁcantly in
TNF-a–stimulated SK-BR-3 cells (Fig. 2A and B). However, unlike-3, MCF7, and MDA-MB-231 breast cancer cells were treated with 10 ng/mL TNF-a
M from 3 independent experiments. ⁄P < 0.05 vs control group. (B) SK-BR-3, MCF7,
roteins were extracted from the treated cells and subjected toWestern blotting with
m a representative experiment. Right, Densitometry; results were normalized to b-
rol group. (C) SK-BR-3 breast cancer cells were treated with 10 ng/mL TNF-a for the
ls and then subjected toWestern blotting with anti-KLF4 antibody. b-Actin was used
er, Densitometry; results were normalized to b-actin. Bars represent the mean ± SEM
ted with 10 ng/mL TNF-a for 0, 1, 2, 3, 4 or 5 days, and cell proliferation was tested
ance was measured at 490 nm. ⁄P < 0.05 vs control group. (E) SK-BR-3 cells were
and analyzed for Annexin-V/7-AAD by FACS using PE Annexin V Apoptosis Detection
periments were summarized (lower). ⁄P < 0.05 vs control group. (E) SK-BR-3 breast
extracted from the treated cells and subjected to Western blotting with antibodies
ing. Bars represent the mean ± SEM from 3 independent experiments. ⁄P < 0.05 vs
Fig. 3. KLF4 promoted SK-BR-3 breast cancer cell apoptosis. (A) SK-BR-3 cells were infected with Ad-GFP and Ad-GFP-KLF4 for 48 h. The exogenous GFP or GFP-KLF4
expression was observed by ﬂuorescence microscopy. Magniﬁcation, 200. (B) SK-BR-3 cells were infected with Ad-GFP and Ad-GFP-KLF4 for 0, 1, 2, 3, 4, or 5 days. Cell
proliferation was tested using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit, and the absorbance was measured at 490 nm. ⁄P < 0.05 vs Ad-GFP group. (C)
HBL-100 breast cells were transfected with si-KLF4 or si-NS for 24 h, and expression of KLF4 was assessed by Western blot analysis. b-Actin was used as a control for equal
protein loading. (D) HBL-100 cells were transfected with si-KLF4 or si-NS, and cell proliferation was tested using the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay Kit at 0, 1, 2, 3, 4, or 5 days after transfection. (E) SK-BR-3 cells were infected with Ad-GFP and Ad-GFP-KLF4 for 72 h and analyzed for Annexin-V/7-AAD by FACS using
the PE Annexin V Apoptosis Detection Kit. One representative experiment is shown (left); results from 3 independent experiments were summarized (right). ⁄P < 0.05 vs Ad-
GFP group. (F) SK-BR-3 cells were infected with Ad-GFP and Ad-GFP-KLF4 for 72 h and then stained with PE-conjugated Annexin V. Pictures show the GFP-tag (green),
annexin V (red), and 40 ,6-diamidino-2-phenylindole (purple). Magniﬁcation, 400. (G) SK-BR-3 cells were infected with Ad-GFP and Ad-GFP-KLF4 for 48 h. The cell lysates
were analyzed by Western blotting with the indicated antibodies, and b-actin was the loading control.
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Fig. 4. KLF4 overexpression suppressed in vivo tumorigenicity of SK-BR-3 cells. (A) Naive or GFP- or GFP-KLF4-overexpressing SK-BR-3 breast cancer cells were injected
subcutaneously into the right mammary fat pad of nude mice at 5  106 cells per site. Tumor volume was monitored every 2 days after subcutaneous injection and tumor
growth curve is shown. Tumor volume was calculated by the formula: V = 1/2  a (length)  b2 (width). ⁄P < 0.05 vs SK-BR-3 group. (B) Tumors were harvested from the mice
14 days after subcutaneous injection and photographed. (C) The volume of the harvested tumors was calculated by the formula: V = 1/2  a (length)  b2 (width). ⁄P < 0.05 vs
SK-BR-3 group. (D) The weight of the tumors was measured. ⁄P < 0.05 vs SK-BR-3 group.
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levels was observed in TNF-a–treated MCF-7 and MDA-MB-231
breast cancer cells (Fig. 2A and B). Moreover, TNF-a increased
KLF4 protein expression in SK-BR-3 cells in a time-dependent man-
ner. As shown in Fig. 2C, 6 h after treatment with 10 ng/mL TNF-a,
KLF4 protein expression increased and that increase was main-
tained until 34 h after treatment in SK-BR-3 cells.
Cell proliferation and apoptosis were also examined in TNF-a–
treated SK-BR-3 breast cancer cells. The MTS cell proliferation
assay was performed, and the results revealed that treatment with
10 ng/mL TNF-a signiﬁcantly decreased SK-BR-3 cell proliferation
(Fig. 2D). Then, apoptosis was examined in TNF-a–stimulated SK-
BR-3 cells. As shown in Fig. 2E, the number of apoptotic cells was
signiﬁcantly greater after treatment with 10 ng/mL TNF-a for
48 h, and knocking down endogenous KLF4 by transfection with
si-KLF4 in TNF-a–treated cells signiﬁcantly attenuated the pro-
apoptotic role of TNF-a in SK-BR-3 breast cancer cells. The apopto-
sis-related genes cleaved caspase-3 and Bax were detected by
Western blotting. The results revealed that the levels of cleaved
caspase-3 and Bax proteins in SK-BR-3 cells increased after TNF-
a treatment in a time-dependent manner (Fig. 2F). These results
revealed that KLF4 expression levels were signiﬁcantly increased
during TNF-a–induced apoptosis, which suggests the important
role of KLF4 in SK-BR-3 breast cancer cell proliferation and
apoptosis.
3.3. KLF4 inhibited proliferation and promoted apoptosis in breast
cancer cells
To validate the roles of KLF4 in breast cancer cell proliferation
and apoptosis, GFP or GFP-KLF4 overexpression was introduced
by infection of the adenovirus vector pAd-GFP or pAd-GFP-KLF4.
Forty-eight hours after infection, the exogenous GFP or GFP-KLF4
expression levels in SK-BR-3 cells were observed by ﬂuorescence
microscopy (Fig. 3A). The MTS proliferation assay was performed
to examine the effects of KLF4 on SK-BR-3 cell proliferation. The
results revealed that GFP-KLF4 overexpression signiﬁcantly
decreased cell proliferation (Fig. 3B). To further identify the roleof KLF4 in breast cancer cell proliferation, we performed MTS pro-
liferation assays in the highly KLF4-expressing breast cell line HBL-
100 in which KLF4 was knocked down by RNAi (Fig. 3C). As shown
in Fig. 3D, proliferative activity was signiﬁcantly higher in KLF4-
knockdown HBL-100 cells, which suggested an anti-proliferative
role of KLF4 in breast cells. Next, we examined apoptosis in
KLF4-overexpressing SK-BR-3 cells by FACS. As shown in Fig. 3C,
the number of apoptotic cells was signiﬁcantly increased after
pAd-GFP-KLF4 overexpression for 72 h. Then, the cells were
stained with PE-conjugated Annexin V. As shown in Fig. 3D,
Annexin V expression on the cell membrane was increased signiﬁ-
cantly in GFP-KLF4-overexpressing SK-BR-3 cells. Moreover, the
apoptosis-related genes, cleaved caspase-3 and Bax, were detected
by Western blotting. The results revealed that the levels of cleaved
caspase-3 and Bax proteins in KLF4-overexpressing SK-BR-3 cells
were signiﬁcantly higher than those in the control group
(Fig. 2E). These results suggest that KLF4 suppressed proliferation
and promoted apoptosis by upregulating the expression of the
apoptosis-related genes caspase-3 and Bax in SK-BR-3 breast cancer
cells.
3.4. Overexpression of KLF4 suppressed SK-BR-3 cell tumorigenicity
in vivo
SK-BR-3 cells were infected with Ad-GFP or Ad-GFP-KLF4 for
48 h to obtain GFP- or GFP-KLF4-overexpressing cells. Then,
5  106 naive, GFP- or GFP-KLF4-overexpressing SK-BR-3 breast
cancer cells were injected into nude mice. After the cells were
injected subcutaneously into the right mammary fat pad of the
nude mice, tumor growth was monitored carefully and the size
of the tumor formed was measured every 2 days. As shown in
Fig. 1A, GFP-KLF4-overexpressing SK-BR-3 cells resulted in signiﬁ-
cantly slower growing and smaller tumors than both naive and
GFP-overexpressing cells. At day 14, the mice were sacriﬁced and
the tumors were harvested, photographed, measured, and
weighed. Tumor volumes in the GFP-KLF4-overexpressing group
were signiﬁcantly smaller than those in the naive or GFP-
overexpressing groups (Fig. 4B and C). There was no signiﬁcant
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group (Fig. 4C). This trend was also reﬂected in the weights of
the tumors, with the average weight of tumors in the GFP-KLF4-
overexpressing group being signiﬁcantly less (Fig. 4D). These
results suggest that overexpression of KLF4 in SK-BR-3 breast can-
cer cells attenuated the ability of SK-BR-3 cells to form tumors in
nude mice.
4. Discussion
KLF4 has been recognized as a tumor suppressor in many types
of cancers [11–13]. However, conﬂicting data exist regarding the
function of KLF4 in breast cancer. Initial studies using immuno-
histochemical and in situ analyses of human breast tumors
reported increased KLF4 expression [29]. KLF4 can also induce can-
cer stem cell (CSC)-like properties that may promote cell migration
and invasion [21], whereas it can also inhibit EMT and block
metastasis [22,25]. Subsequent reports have shown that KLF4
mRNA levels are decreased in breast cancer tissues, relative to nor-
mal tissue, and inversely correlated with increasing tumor grade
[23]. KLF4 was also reported to participate estrogen receptor sig-
naling by upregulating the estrogen level in breast cancer cells,
and ablation of KLF4 inhibits estrogen-induced growth of tumor
cells [30]. Despite these ﬁndings, the exact roles of KLF4 in breast
cancer cell proliferation and apoptosis remain unclear. This study
demonstrated that KLF4 expression is lost in breast inﬁltrating
ductal carcinoma tissues and several breast cancer cell lines, and
KLF4 exhibits an anti-proliferative and pro-apoptotic role in SK-
BR-3 breast cancer cells, which suggested a role for KLF4 as a
tumor suppressor.
TNF-a is a cytokine that acts as an important mediator of the
apoptotic process that also demonstrates selective cytotoxicity
against malignant breast tumor cells [31,32]. It can also increase
expression of KLF4 in vascular smooth muscle cells [33].
Therefore, we examined whether KLF4 participates TNF-a–induced
breast cancer cell apoptosis. In this study, treatment of SK-BR-3
breast cancer cells with 10 ng/mL TNF-a signiﬁcantly suppressed
proliferation and induced apoptosis, as well as induced the expres-
sion of apoptosis-related genes, including cleaved caspase-3 and
Bax. Recently, KLF4 has been shown to be transcriptionally acti-
vated by p53 following DNA damage [23] and to be involved in
breast cancer cell apoptosis [22,24,34], suggesting its potential role
as a tumorigenic suppressor. Moreover, KLF4 suppresses histone
deacetylase inhibitor-induced caspase activation and the stress-
activated protein kinase pathway by targeting p57(Kip2) [35]. In
this study, KLF4 protein and mRNA expression levels were
signiﬁcantly increased in the TNF-a–induced apoptotic process
in SK-BR-3 cells, which suggests the participation of KLF4 in
SK-BR-3 breast cancer cell apoptosis.
KLF4 is an important modulator of cell proliferation, differentia-
tion, and transformation and has recently been considered a possi-
ble prognostic factor in breast cancer [36]. The mechanisms of
KLF4 in SK-BR-3 cell proliferation and apoptosis remain unknown.
In this study, KLF4 overexpression was introduced by infection of
the adenovirus vector pAd-GFP-KLF4 to validate the roles of KLF4
in SK-BR-3 breast cancer cell, and the results revealed induction
of apoptosis and apoptosis-related gene expression and signiﬁ-
cantly decreased cell proliferation. Tumorigenic progression is a
multistep process. Our results show that KLF4 overexpression
progressively suppressed SK-BR-3 mammary tumorigenicity
in a mouse model.
In summary, we focused on the functions of KLF4 in breast can-
cer in the present study and identiﬁed the anti-proliferative and
pro-apoptotic roles of KLF4 by targeting caspase-3 and Bax.
While these ﬁndings shed some light on the function of KLF4 inbreast cancer apoptosis and mammary tumorigenic progression
using a mouse model, it is important that additional models, both
in vitro and in vivo, representing various breast cancer subtypes, be
examined. As KLF4 plays a role in the induction and maintenance
of iPSCs [8], it is also important to determine whether similar reg-
ulation occurs in mammary and tumor stem cells. Further elucidat-
ing the crucial functions of KLF4 in breast cancer formation and
processing will better deﬁne the utility of KLF4 as a target for
diagnostic and therapeutic interventions.
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